SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Felix B who wrote (1914)5/5/2016 10:05:32 AM
From: Miljenko Zuanic  Respond to of 3559
 
Yes, therapeutic dose is 1-3 mg (every 8 weeks for PFE candidate). That is very, very low dose for antibody...so will pain relief be sufficient to balance safety risk???

On a 1Q revenue note, as predicted (I am not sure why is so difficult to do SIMPLE MATH...analysts predictions???), EYLEA sale WW are going up at 25-30%, relative to 2015..or closing to $6B mark. Also, based on EYLEA revenue REGN MC should be @45-48B.

finance.yahoo.com